Literature DB >> 18577396

The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle.

Paul D Shilling1, David Feifel.   

Abstract

Preliminary evidence suggests that the neuropeptide, neurotensin (NT) may regulate fear/anxiety circuits. We investigated the effects of PD149163, a NT1 receptor agonist, on fear-potentiated startle (FPS). Sprague Dawley rats were trained to associate a white light with a mild foot shock. In one experiment, animals were treated with either subcutaneous vehicle or PD149163 (0.01, 0.1 or 1.0 mg/kg) 24 h after training. Twenty minutes later their acoustic startle response in the presence or absence of the white light was tested. In a second experiment, saline and 1.0 mg/kg PD149163 were tested using a separate group of rats. In the first experiment, PD149163 produced a non-significant decrease in baseline acoustic startle at all three doses. As expected, saline-treated rats exhibited significant FPS. An ANOVA of percentage FPS revealed no significant effect of treatment group overall but the high dose group did not display FPS strongly suggesting an FPS effect at this dose. This finding was confirmed in the second experiment where the high dose of PD149163 reduced percent FPS relative to saline (P < 0.05). These data suggest that systemically administered NT1 agonists modulate the neural circuitry that regulates fear and anxiety to produce dose-dependent anxiolytic-like effects on FPS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18577396      PMCID: PMC4215568          DOI: 10.1016/j.pbb.2008.05.025

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  50 in total

1.  Neurotensin receptor agonists and antagonists for schizophrenia.

Authors:  Elliott Richelson; Paul A Fredrickson; Mona M Boules
Journal:  Am J Psychiatry       Date:  2005-03       Impact factor: 18.112

2.  Selective reduction in amygdala volume in pediatric anxiety disorders: a voxel-based morphometry investigation.

Authors:  Michael P Milham; Allison C Nugent; Wayne C Drevets; Daniel P Dickstein; Ellen Leibenluft; Monique Ernst; Dennis Charney; Daniel S Pine
Journal:  Biol Psychiatry       Date:  2005-05-01       Impact factor: 13.382

3.  Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol.

Authors:  B Cusack; M Boules; B M Tyler; A Fauq; D J McCormick; E Richelson
Journal:  Brain Res       Date:  2000-02-21       Impact factor: 3.252

4.  Corticolimbic blood flow in posttraumatic stress disorder during script-driven imagery.

Authors:  Jennifer C Britton; K Luan Phan; Stephan F Taylor; Lorraine M Fig; Israel Liberzon
Journal:  Biol Psychiatry       Date:  2005-04-15       Impact factor: 13.382

5.  Amygdala responses to human faces in obsessive-compulsive disorder.

Authors:  Paul A Cannistraro; Christopher I Wright; Michelle M Wedig; Brian Martis; Lisa M Shin; Sabine Wilhelm; Scott L Rauch
Journal:  Biol Psychiatry       Date:  2004-12-15       Impact factor: 13.382

6.  Centrally administered neurotensin suppresses locomotor hyperactivity induced by d-amphetamine but not by scopolamine or caffeine.

Authors:  K M Skoog; S T Cain; C B Nemeroff
Journal:  Neuropharmacology       Date:  1986-07       Impact factor: 5.250

7.  Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects.

Authors:  David Feifel; Gilia Melendez; Paul D Shilling
Journal:  Neuropsychopharmacology       Date:  2004-04       Impact factor: 7.853

8.  The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat.

Authors:  Kimberly A Petrie; Michael Bubser; Cheryl D Casey; M Duff Davis; Bryan L Roth; Ariel Y Deutch
Journal:  Neuropsychopharmacology       Date:  2004-10       Impact factor: 7.853

Review 9.  Pharmacotherapy of generalized anxiety disorder.

Authors:  Karl Rickels; Moira Rynn
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

10.  Inhibition of fear potentiated startle in rats following peripheral administration of secretin.

Authors:  Karyn Myers; Martin Goulet; James Rusche; Richard Boismenu; Michael Davis
Journal:  Psychopharmacology (Berl)       Date:  2003-10-29       Impact factor: 4.530

View more
  13 in total

1.  The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats.

Authors:  Elizabeth N Holly; Bree Ebrecht; Adam J Prus
Journal:  Eur Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 4.600

2.  Diverse actions of the modulatory peptide neurotensin on central synaptic transmission.

Authors:  Christopher W Tschumi; Michael J Beckstead
Journal:  Eur J Neurosci       Date:  2018-02-28       Impact factor: 3.386

3.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

Review 4.  Neurotensin in reward processes.

Authors:  María Luisa Torruella-Suárez; Zoe A McElligott
Journal:  Neuropharmacology       Date:  2020-02-11       Impact factor: 5.250

5.  Altered sleep and affect in the neurotensin receptor 1 knockout mouse.

Authors:  Karrie Fitzpatrick; Christopher J Winrow; Anthony L Gotter; Joshua Millstein; Janna Arbuzova; Joseph Brunner; Andrew Kasarskis; Martha H Vitaterna; John J Renger; Fred W Turek
Journal:  Sleep       Date:  2012-07-01       Impact factor: 5.849

6.  Sensorimotor gating in neurotensin-1 receptor null mice.

Authors:  D Feifel; Z Pang; P D Shilling; G Melendez; R Schreiber; D Button
Journal:  Neuropharmacology       Date:  2009-07-09       Impact factor: 5.250

7.  The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature.

Authors:  David Feifel; Joseph Goldenberg; Gilia Melendez; Paul D Shilling
Journal:  Neuropharmacology       Date:  2009-07-09       Impact factor: 5.250

Review 8.  Insight from animal models of environmentally driven epigenetic changes in the developing and adult brain.

Authors:  Tiffany S Doherty; Tania L Roth
Journal:  Dev Psychopathol       Date:  2016-09-30

9.  Acute, but not repeated, administration of the neurotensin NTS1 receptor agonist PD149163 decreases conditioned footshock-induced ultrasonic vocalizations in rats.

Authors:  Adam J Prus; Todd M Hillhouse; Amber L LaCrosse
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-11-23       Impact factor: 5.067

10.  Ionic and signaling mechanisms involved in neurotensin-mediated excitation of central amygdala neurons.

Authors:  Saobo Lei; Binqi Hu
Journal:  Neuropharmacology       Date:  2021-07-14       Impact factor: 5.273

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.